Cartesian Therapeutics financials
$7.24+0.42%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $78.0K | $947.0K | $452.0K | $298.0K | $1.1M | — | $387.0K | $33.4M | $5.8M | $8.3M |
| Gross profit | $0.00 | $78.0K | $947.0K | $452.0K | $298.0K | $1.1M | — | $387.0K | $33.4M | $5.8M | $8.3M |
| Gross margin | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$29.2M | -$26.5M | -$78.6M | -$21.1M | -$21.8M | -$21.9M | — | -$17.6M | $13.8M | -$13.3M | -$36.3M |
| Net income | $13.7M | -$39.2M | -$92.6M | -$35.9M | $13.3M | -$17.7M | — | -$24.2M | $9.6M | -$56.8M | -$215.2M |
| Net margin | — | −50233.3% | −9775.7% | −7942.9% | 4449.0% | −1610.0% | — | −6248.8% | 28.8% | −973.0% | −2603.5% |
| Diluted EPS | $0.46 | $-1.46 | $-3.62 | $-1.38 | $0.50 | $-0.68 | — | $-1.13 | $0.54 | $-10.50 | $-40.64 |
| EBITDA | -$28.4M | -$25.9M | -$21.3M | -$20.5M | -$21.2M | -$20.7M | $486.0K | -$17.3M | $13.4M | -$12.7M | -$36.6M |
| Operating cash flow | -$21.1M | -$22.1M | -$17.7M | -$15.6M | -$17.5M | -$23.1M | -$7.0M | $13.7M | -$14.4M | -$15.9M | -$23.3M |
| Free cash flow | -$21.4M | -$22.2M | -$18.2M | -$16.9M | -$20.1M | -$24.2M | -$7.7M | $7.5M | -$16.0M | -$16.5M | -$23.4M |
| Diluted shares | 29.9M | 26.9M | 25.5M | 26.0M | 26.4M | 25.9M | 24.8M | 21.5M | 17.8M | 5.4M | 5.3M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $147.6M | $118.6M | $125.1M | $143.4M | $160.3M | $180.4M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $52.9M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $318.6M | $288.4M | $296.4M | $372.7M | $388.9M | $409.1M |
| Total liabilities | $443.9M | $436.5M | $422.7M | $408.5M | $39.3M | $430.9M |
| Shareholders' equity | -$125.2M | -$148.1M | -$126.2M | -$35.8M | $349.6M | -$21.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology